## Form **8937**(December 2017) Department of the Treasury

Internal Revenue Service

### Report of Organizational Actions Affecting Basis of Securities

► See separate instructions.

OMB No. 1545-0123

Part Reporting Issuer		
1 Issuer's name	2 Issuer's employer identification number (EIN)	
Enliven Therapeutics, Inc. (F/	/K/A Imara Inc.)	81-1523849
3 Name of contact for additional information	4 Telephone No. of contact	5 Email address of contact
Investor Relations	720-647-8519	IR@EnlivenTherapeutics.com
6 Number and street (or P.O. box if mail is not of	delivered to street address) of contact	7 City, town, or post office, state, and ZIP code of contact
6200 Lookout Road		Boulder, CO 80301
8 Date of action	9 Classification and description	
	Reverse Merger	
February 23, 2023		
10 CUSIP number 11 Serial number(s)	) 12 Ticker symbol	13 Account number(s)
29337E102	ELVN	
Part II Organizational Action Attack	n additional statements if needed. See	back of form for additional questions.
14 Describe the organizational action and, if ap	oplicable, the date of the action or the date	against which shareholders' ownership is measured for
the action ▶ On February 23, 20	023, a wholly-owned subsid	iary of Imara Inc. ("Imara")
margad with and into Enliven		

- Describe the organizational action and, if applicable, the date of the action or the date against which shareholders' ownership is measured for the action ▶ On February 23, 2023, a wholly-owned subsidiary of Imara Inc. ("Imara")

  merged with and into Enliven Therapeutics, Inc. ("Old Enliven"), with Old Enliven surviving the merger. As a result, Old Enliven became a wholly-owned subsidiary of Imara.

  Following the closing of the merger, Imara changed its name to Enliven Therapeutics, Inc. ("New Enliven"). Beginning with the opening of trading on February 24, 2023, New Enliven's common stock traded on the NASDAQ Global Select Market under ticker symbol "ELVN" with a new CUSIP number 29337E102. The transaction was intended to qualify as a reorganization within the meaning of sections 368(a)(1)(A) and 368(a)(2)(E) and/or as a non-taxable exchange under section 351(a).
- Describe the quantitative effect of the organizational action on the basis of the security in the hands of a U.S. taxpayer as an adjustment per share or as a percentage of old basis ▶ Immediately after the merger, there were approximately 41.1 million shares of New Enliven common stock outstanding, with prior New Enliven stockholders owning approximately 16% of the outstanding shares of New Enliven on a fully-diluted basis and Old Enliven stockholders owning approximately 84% of the outstanding shares of the combined company on a fully-diluted basis. Each share of capital stock of Old Enliven was exchanged for the right to receive a certain number of shares of common stock of New Enliven, par value of \$0.001 per share.

No fractional shares were issued in connection with this merger. Any stockholder of New Enliven who would otherwise have been entitled to a fractional share received a cash payment instead of such fractional share.

Describe the calculation of the change in basis and the data that supports the calculation, such as the market values of securities and the valuation dates ▶ The stockholders' calculated basis in the New Enliven common stock will be based upon (i) their basis in their Old Enliven common stock, (ii) decreased by any cash or other non-stock consideration received and (iii) increased by any gain recognized in the transaction. Where one share of New Enliven stock was received in exchange for more than one share of Old Enliven stock, the basis of the shares of stock surrendered must be allocated to the share of stock received in a manner that minimizes the disparity in the holding period of the surrendered shares of stock whose basis is allocated to any particular share of stock received. See the rules of Treas. Reg. Sec.1.358-2.

Part II	Organizational Action (continued)		
17 List th	ne applicable Internal Revenue Code section(s) and subsection(s) upon which the tax t	reatment is based >	•
Section	s 368(a)(1)(A) and (a)(2)(E), 351, 354, 356,1032, T	reas. Reg. S	Sec. 1.358-2, and
Treas.	Reg. Sec. 1.358-6		
<b>18</b> Can a	ny resulting loss be recognized?▶ Any stockholder of New Enlive	n who receiv	red cash in lieu
of a fr	actional share of New Enliven common stock will rec	ognize gain	or loss equal to
the dif	ference between the amount of cash received and the	portion of	the stockholder's
aggrega	te adjusted tax basis in the shares of Old Enliven	common stock	allocable to
the fra	ctional share.		
19 Provid	de any other information necessary to implement the adjustment, such as the reportab	le tax year ►	
The tra	nsaction occurred during the calendar year ending D	ecember 31,	2023.
	der penalties of perjury, I declare that I have examined this return, including accompanying sche ief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all info		
	DocuSigned by:	imation of which prepa	arer rias arry knowledge.
Sign	Boya Halil	4/10/	/2023
Here   Sig	nature • CADOOO/31/45/240F	Date ►	
	—— Онроват от A0048E		
Pri	nt your name ▶ Ben Hohl		Financial Officer
Paid	Print/Type preparer's name  Preparer's signature	Date	Check if PTIN
Prepare	Nickolas Zheng	4/10/2023	self-employed P01465726
Use Onl	y Firm's name ▶ Deloitte Tax LLP		Firm's EIN ▶86-1065772
,	Firm's address ▶ 200 Berkeley Street Boston, MA 02116		Phone no. 617-437-2000

Send Form 8937 (including accompanying statements) to: Department of the Treasury, Internal Revenue Service, Ogden, UT 84201-0054

# Form **8937**(December 2017) Department of the Treasury Internal Revenue Service

Part I Reporting Issuer

### Report of Organizational Actions Affecting Basis of Securities

► See separate instructions.

OMB No. 1545-0123

1 Issuer's name	2 Issuer's employer identification number (EIN)		
Enliven Therapeutics, Inc. (F	K/A Ima	ıra Inc.)	81-1523849
3 Name of contact for additional information	4 Telephon	e No. of contact	5 Email address of contact
Investor Relations	720-647-		IR@EnlivenTherapeutics.com
6 Number and street (or P.O. box if mail is not	delivered to	street address) of contact	<b>7</b> City, town, or post office, state, and ZIP code of contact
6200 Lookout Road	1		Boulder, CO 80301
8 Date of action		sification and description	
_ ,	Rever	se Stock Split	
February 23, 2023  10 CUSIP number	(a)	42 Tieleer eyenhel	42 Account number(c)
10 CUSIP number 11 Serial number	(S)	12 Ticker symbol	13 Account number(s)
		E1 77N1	
Part II Organizational Action Atta	ch additional	ELVN Letatements if needed See b	ack of form for additional questions.
			gainst which shareholders' ownership is measured for
the action ► Please see attach		e date of the action of the date a	gainst which shareholders ownership is measured for
ricacion Prease see attact	menc.		
-			
-			
4F Describe the averagination offers of the same	:		the bearing of a LLC town areas on adjustment in a
			n the hands of a U.S. taxpayer as an adjustment per
share or as a percentage of old basis ▶			
stockholder, the stockholder		one snare of Imara	common stock as a
result of the reverse stock s	split.		
•		• •	n, such as the market values of securities and the
· · · · · · · · · · · · · · · · · · ·			pe a recapitalization transaction
			enue Code of 1986, as amended
(the "Code"). The stockholder	r's calcu	lated basis in the	New Enliven common stock will be
based upon (i) their basis in	their O	old Enliven common s	tock, (ii) decreased by any cash
or other non-stock considerat	ion rece	eived and (iii) incr	eased by any gain recognized in
the transaction. Where one sh	nare of N	Iew Enliven stock wa	s received in exchange for more
than one share of Old Enliver	stock,	the basis of the sh	ares of stock surrendered must be
allocated to the share of sto	ck recei	ved in a manner tha	t minimizes the disparity in the

holding period of the surrendered shares of stock whose basis is allocated to any particular share of stock received. See the rules of Treas. Reg. Sec. 1.358-2.

Part	Ц (	rgaر	nızatı	onal A	ction	(contin	ued)											
												hich the ta						
Secti	ons	368	(a)(1	L)(E)	, 35	4, 35	56,	<u>358,</u>	and	103	2, a	nd Trea	as. Re	eg. Se	ec.1	.358-2		
<b>18</b> C	an any	resul	ting loss	s be reco	gnized1	? ► <u>Ar</u>	ny I	mara	sha	reho	lder	that r	eceiv	es ca	ash :	in lie	u of a	a
fract	iona	ıl s	hare	of Ir	mara	commo	on s	tock	as	a re	sult	of the	e reve	erse s	stoc	k spli	t sho	uld
												to the						
												asis ir						
stock	sur	ren	<u>.derec</u>	<u>l that</u>	t is	allo	cate	d to	suc	h fr	acti	onal sh	nare d	of Ima	ara	common	stoc	k.
<b>19</b> Pi	rovide	anv o	ther info	rmation	necess	arv to in	nplem	ent the	e adiust	ment.	such as	the report	able tax	vear ▶				
		-				-			-			ending		-	31,	2023.		
	I																	
												mpanying so ased on all ir						y knowledge and e.
Sign	20,			uSigned by	•	20014.41	o o. <sub> </sub>	,, op a. o	. (01.101 1.		00.7.0 20				. р. ора.	o. nao any	ooug	<b>.</b>
Here		Bass Halel							4/10/2023									
	Signat	ture 🟲		U (10111) 00973FA53	/ //0E								_ Date	<b>-</b>				
	D												<b>-</b>	Oh:	of T	Zinana:	1-1 O1	Ffigo:
	Print y			en Ho parer's na				Prepar	er's signa	ature			Title Date		er F	inanc:	PTIN	
Paid				zhens na Zhen				19.	chola	1 (76	19				,	Check	IT	1465726
Prepa	ושוג		s name		loitt	е Тэч	- Т.Т.	لن <i>دلال</i> D	NOW.		-17		4/	10/2023	•		_	1465726
Use C	חוא			• ► 200					Bost	ton	MΔ (	2116						37-2000

Send Form 8937 (including accompanying statements) to: Department of the Treasury, Internal Revenue Service, Ogden, UT 84201-0054

## FORM 8937 – REPORT OF ORGANIZATIONAL ACTIONS AFFECTING BASIS OF SECURITIES Reverse Stock Split

Enliven Therapeutics, Inc. (F/K/A Imara Inc.) 81-1523849

#### **ATTACHMENT 1**

#### Part II

**14.** On February 23, 2023, a wholly owned subsidiary of Imara Inc. ("Imara") merged with and into Enliven Therapeutics, Inc. ("Old Enliven"), with Old Enliven surviving the merger. As a result, Old Enliven became a wholly owned subsidiary of Imara. Following the closing of the merger, Imara changed its name to Enliven Therapeutics, Inc. ("New Enliven").

Immediately prior to the closing of the merger, Imara executed a 1-for-4 reverse stock split of its common stock, i.e., for each 4 shares held one share was received. Immediately prior to the reverse stock split, Imara obtained its stockholder approval to increase its authorized common shares from 200 million to 400 million. The reverse stock split proportionately reduced the number of authorized shares of Imara's common stock from 400 million shares to 100 million shares. The number of outstanding common shares was also reduced as a result of the reverse stock split.

The reverse stock split affected all issued shares of Imara common stock, as well as the number of authorized shares of Imara's common stock and the number of shares of common stock available for issuance under Imara's equity incentive plan; however, it did not change the par value of Imara's common stock or the authorized and outstanding number of shares of Imara's preferred stock. No fractional shares of common stock were issued in connection with the reverse stock split; any stockholders who would otherwise have been due a fractional share of common stock received a proportional cash payment instead of such fractional share.

## Form **8937**(December 2017) Department of the Treasury

### Report of Organizational Actions Affecting Basis of Securities

► See separate instructions

OMB No. 1545-0123

Internal Revenue Service			See separate instructions.	
Part I Reporting I	ssuer			
1 Issuer's name		2 Issuer's employer identification number (EIN)		
Enliven Therapeut	ics. Inc. (F	81-1523849		
3 Name of contact for add		5 Email address of contact		
Investor Relation		720-647		IR@EnlivenTherapeutics.com
6 Number and street (or P	.O. box if mail is not	delivered to	street address) of contact	7 City, town, or post office, state, and ZIP code of contact
6200 Lookout Road		Boulder, CO 80301		
8 Date of action			sification and description Change	
February 23, 2023		,	1	
10 CUSIP number	11 Serial number(	S)	12 Ticker symbol	13 Account number(s)
Part II Organization	nal Action Attac	h additiona	ELVN al statements if needed. See	back of form for additional questions.
				against which shareholders' ownership is measured for
				liary of Imara Inc. ("Imara")
			<u>-</u>	Inliven"), with Old Enliven
				wholly-owned subsidiary of Imara.
				name to Enliven Therapeutics, Inc.
("New Enliven").	sing of the	merger,	Illiara Changed Its	name to Emiliven inerapeutics, inc.
( New Ellitvell ).				
45 5 7 1 1				
				in the hands of a U.S. taxpayer as an adjustment per
	_			dered to be a reorganization under
				he basis of a share considered to
			e basıs of a share	considered to be surrendered in
exchange for that	share recei	ved.		
40 D ii ii l l iii				
valuation dates► <u>If</u>	the name ch	ange is	considered to be a	ion, such as the market values of securities and the reorganization under
<u>section 368(a)(1)</u>	(F) with a s	ection 3	354 exchange then t	he basis of a share considered to
			e basis of a share	considered to be surrendered in
exchange for that	share recei	ved.		

David		Opposite tiered Action (c. 1)			
Part	Ш	Organizational Action (continued)			
		applicable Internal Revenue Code section(s) and subsection(s) upon which the tax tr		is based I	·
sect:	ion :	368(a)(1)(F), 354, 358, and Treas. Reg. Sec. 1.358	-2.		
<b>18</b> C	an any	y resulting loss be recognized? ► NO			
<b>19</b> P	rovide	e any other information necessary to implement the adjustment, such as the reportab	e tax ve	ar ▶	
		saction occurred during the calendar year ending De			2023.
	0111	Sacoton coourted dataing one caronada year ending b	30011130	01 01,	2020.
		er penalties of perjury, I declare that I have examined this return, including accompanying sched			
	belief	f, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all infor DocuSigned by:	mation of	which prep	arer has any knowledge.
Sign		a 11 / I		4 /10 /	2022
Here	Signa	ature by BUN HOW	Date ►	4/10/	2023
	1	C4D00973FA5349E			
	Print	your name ▶ Ben Hohl	Title►	Chief	Financial Officer
Paid		Print/Type preparer's name Preparer's signature	Date		Check if PTIN
Prepa	arer	Nickolas Zheng	4/10/	2023	self-employed P01465726
Use (		Firm's name ▶ Deloitte Tax LLP			Firm's EIN ▶86-1065772
	y	Firm's address ▶ 200 Berkeley Street Boston, MA 02116			Phone no. 617-437-2000

Send Form 8937 (including accompanying statements) to: Department of the Treasury, Internal Revenue Service, Ogden, UT 84201-0054

# Form **8937**(December 2017) Department of the Treasury Internal Revenue Service

### Report of Organizational Actions Affecting Basis of Securities

► See separate instructions.

OMB No. 1545-0123

Part I Reporting I	ssuer		•	!
1 Issuer's name		2 Issuer's employer identification number (EIN)		
		,		
Enliven Therapeut	ics, Inc. (F	81-1523849		
3 Name of contact for add	litional information	5 Email address of contact		
Investor Relation		IR@EnlivenTherapeutics.com		
6 Number and street (or P	O. box if mail is not	delivered to	street address) of contact	7 City, town, or post office, state, and ZIP code of contact
6000 - 1 1				- 11 co 00001
6200 Lookout Road  8 Date of action		Boulder, CO 80301		
• Date of action			sification and description	ingent Value Right (CVR)
February 23, 2023		Issua	nce or the cont	ingene value Right (CVR)
10 CUSIP number	11 Serial number	(s)	12 Ticker symbol	13 Account number(s)
		,	,	, ,
Part II Organization	nal Action Atta	ch additiona	I statements if needed.	See back of form for additional questions.
_			e date of the action or the	date against which shareholders' ownership is measured for
the action $\triangleright$ Pleas	e see attach	ment.		
15 Describe the quantitat	ive effect of the orga	anizational act	tion on the basis of the se	ecurity in the hands of a U.S. taxpayer as an adjustment per
	_			k outstanding as of February 22, 2023
				cordance with the terms and conditions
of a Contingent V	alue Right A	greement	. To the extent	the distribution on a share of Imara
common stock exce	eds a shareh	older's	allocable porti	on of the current and
accumulated earni	ngs and prof	its with	respect to the	share of stock, there would be a
reduction to the	shareholder'	s basis	in the share of	stock to the extent of available
basis in the shar	e.			
16 Describe the calculation	on of the change in h	agic and the	data that augments the ag	lculation, such as the market values of securities and the
	_			reholder's basis in the share of stock
				e distribution on a share of Imara
				on of the current and
accumulated earni				
accamaracca cariir	iigb ana proi	TCD WICH	r respect to the	blidle of become

Part l	Ι (	Organizational Action (continued)		•
		applicable Internal Revenue Code section(s) and subsection(s) upon which the tax	treatment is based	-
Secti	on .	301(c)		
<b>18</b> C	an any	y resulting loss be recognized? ► NO		
<b>19</b> Pi	rovido	any other information necessary to implement the adjustment, such as the reporta	able tay year	
		saction occurred during the calendar year ending		2023.
1110 0	<i></i>	bacton cocarrea daring the carenaar fear charing	December 317	2023.
		er penalties of perjury, I declare that I have examined this return, including accompanying sch f, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all inf		
O:	Dellei	DocuSigned by:	ormation of which prepare	arer has any knowledge.
Sign Here		Bur Hold.	4/10/	2023
11010	Signa	ature C4D00973FA5349E	_ Date ►	
	Drint	your name ▶ Ben Hohl	Title Chief	Financial Officer
De!=!	Frint	Print/Type preparer's name  Preparer's signature  Preparer's signature	Title ► Chief Date	DTINI
Paid	aror	Nickolas Zheng	4/10/2023	Check if First self-employed P01465726
Prepa Use C				Firm's EIN ▶86-1065772
	J.111y	Firm's address ▶ 200 Berkeley Street Boston, MA 02116		Phone no. 617-437-2000
Send Fo	orm 89	937 (including accompanying statements) to: Department of the Treasury, Internal I	Revenue Service, Og	den, UT 84201-0054

## FORM 8937 – REPORT OF ORGANIZATIONAL ACTIONS AFFECTING BASIS OF SECURITIES Issuance of the Contingent Value Right (CVR)

Enliven Therapeutics, Inc. (F/K/A Imara Inc.) 81-1523849

#### ATTACHMENT 1

#### Part II

**14.** On February 23, 2023, a wholly-owned subsidiary of Imara Inc. ("Imara") merged with and into Enliven Therapeutics, Inc. ("Old Enliven"), with Old Enliven surviving the merger. As a result, Old Enliven became a wholly-owned subsidiary of Imara. Following the closing of the merger, Imara changed its name to Enliven Therapeutics, Inc. ("New Enliven").

On February 22, 2023, prior to the closing of the merger, Imara issued one contingent value right ("CVR") for each outstanding share of Imara common stock held by stockholders of Imara as of February 22, 2023. The CVR is a non-transferrable contractual right to receive payment upon the occurrence of certain events related to a prior transaction. Imara will report the issuance of the CVRs to Imara stockholders as a distribution of property with respect to Imara common stock. Each Imara stockholder will be treated as receiving a distribution in an amount equal to the fair market value of the CVRs issued to such Imara stockholder on the date of the issuance.